BioAtla, Inc. Contracts & Agreements
59 Contracts & Agreements
- Business Finance (20 contracts)
- Business Operations (7)
- Human Resources (11)
- Intellectual Property (5)
- Real Estate (2)
- Uncategorized (14)
- Form of Securities Purchase Agreement, dated as of December 19, 2024 (Filed With SEC on December 20, 2024)
- Form of Warrant (Filed With SEC on December 20, 2024)
- Global Transaction Agreement between BioAtla, Inc. and Himalaya Therapeutics SEZC, dated as of September 23, 2024 (Filed With SEC on September 23, 2024)
- License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of September 23, 2024 (Filed With SEC on September 23, 2024)
- Form of Non-Employee Director Restricted Stock Unit Agreement (Filed With SEC on August 8, 2024)
- Amended and Restated Director Compensation Policy (Filed With SEC on August 8, 2024)
- Form of Restricted Stock Unit Agreement (Filed With SEC on May 14, 2024)
- China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company, as amended (Filed With SEC on May 14, 2024)
- Form of Employee Stock Option Agreement (Filed With SEC on March 26, 2024)
- Form of Non-Employee Director Stock Option Agreement (Filed With SEC on March 26, 2024)
- First Amendment to Lease with HCP Torreyana, dated January 16, 2019 (Filed With SEC on March 26, 2024)
- Description of Securities (Filed With SEC on March 26, 2024)
- Form of Stock Option Agreement (Filed With SEC on August 1, 2023)
- Form of Stock Option Agreement (25%) (Filed With SEC on August 1, 2023)
- Form of Stock Option Agreement (50%) (Filed With SEC on August 1, 2023)
- Open Market Sale AgreementSM, dated as of January 6, 2023, between BioAtla, Inc. and Jefferies LLC (Filed With SEC on January 6, 2023)
- Underwriting Agreement, dated November 4, 2022, by and between BioAtla, Inc. and J.P. Morgan Securities LLC (Filed With SEC on November 7, 2022)
- Master Clinical Trial Collaboration Agreement, dated January 5, 2022, by and between BioAtla, Inc. and Bristol-Myers Squibb Company (Filed With SEC on November 4, 2022)
- BioAtla, Inc. Management Change of Control Severance Plan (Filed With SEC on September 21, 2022)
- China Clinical Trial Services Agreement, dated April 8, 2022, by and between BioAtla, Inc. and Himalaya Therapeutics Limited Company (Filed With SEC on August 9, 2022)
- BioAtla Director Compensation Policy (Filed With SEC on February 28, 2022)
- Amendment No. 3 to Global Co-Development and Collaboration Agreement between BioAtla, Inc. and BeiGene, Ltd (Filed With SEC on February 28, 2022)
- Amendment No. 1 to Employee Share Purchase Plan (Filed With SEC on February 28, 2022)
- Amendment No. 2 to 2020 Equity Incentive Plan (Filed With SEC on February 28, 2022)
- Offer Letter between BioAtla, LLC and Christian Vasquez, dated October 22, 2015 (Filed With SEC on February 28, 2022)
- Offer Letter between BioAtla, LLC and Eric Sievers, dated June 17, 2019 (Filed With SEC on February 28, 2022)
- Severance Agreement between BioAtla, LLC and Richard Waldron, dated July 1, 2018 (Filed With SEC on February 28, 2022)
- Offer Letter between BioAtla, LLC and Richard Waldron, dated October 23, 2013 (Filed With SEC on February 28, 2022)
- Description of Securities (Filed With SEC on February 28, 2022)
- Form of Employee Stock Option Agreement (Filed With SEC on November 15, 2021)
- Form of Non-Employee Director Stock Option Agreement (Filed With SEC on November 15, 2021)
- Form of Stock Purchase Agreement (Filed With SEC on September 29, 2021)
- Transition Agreement by and between BioAtla, Inc. and Carolyn Anderson Short, dated March 23, 2021 (Filed With SEC on May 12, 2021)
- Description of Securities (Filed With SEC on March 24, 2021)
- 2020 Employee Stock Purchase Plan (Filed With SEC on December 8, 2020)
- Form of Underwriting Agreement (Filed With SEC on December 8, 2020)
- Specimen Common Stock Certificate evidencing the shares of common stock (Filed With SEC on December 8, 2020)
- Investors Rights Agreement, dated July 13, 2020 (Filed With SEC on December 8, 2020)
- Right of First Refusal and Co-Sale Agreement, dated July 13, 2020 (Filed With SEC on December 8, 2020)
- Voting Agreement, dated July 13, 2020 (Filed With SEC on December 8, 2020)
- 2020 Equity Incentive Plan (Filed With SEC on December 8, 2020)
- Form of Restricted Stock Agreement (Filed With SEC on December 8, 2020)
- Employment Letter Agreement between BioAtla, LLC and Jay Short, as amended by the Letter Amendment dated October 1, 2011 (Filed With SEC on December 8, 2020)
- Offer Letter between BioAtla, LLC and Carolyn Short, dated November 30, 2015 (Filed With SEC on December 8, 2020)
- Severance Agreement between BioAtla, LLC and Jay Short, dated July 1, 2018 (Filed With SEC on December 8, 2020)
- Offer Letter between BioAtla, LLC and Scott Smith, dated August 2, 2018 (Filed With SEC on December 8, 2020)
- Letter Agreement between BioAtla, LLC and Scott Smith, dated August 3, 2018 (Filed With SEC on December 8, 2020)
- Severance Agreement between BioAtla, LLC and Scott Smith, dated August 20, 2018 (Filed With SEC on December 8, 2020)
- Severance Agreement between BioAtla, LLC and Carolyn Short, as amended by the Amended Severance Agreement between BioAtla, LLC and Carolyn Short, dated April 1, 2020 (Filed With SEC on December 8, 2020)
- Form of Indemnification Agreement between the Registrant and each of its executive officers (Filed With SEC on December 8, 2020)
- Lease Agreement with HCP Torreyana, LLC, dated June 2, 2017, as amended by First Amendment to Lease, dated January 16, 2019 (Filed With SEC on December 8, 2020)
- Exclusive Rights Agreement with Himalaya SEZC, dated January 1, 2020 (Filed With SEC on November 13, 2020)
- Payment Protection Program Promissory Note dated April 22, 2020, by and between BioAlta, LLC and City National Bank (Filed With SEC on November 13, 2020)
- Royalty Sharing Agreement with BioAtla Holdings, LLC, dated January 1, 2020 (Filed With SEC on November 13, 2020)
- Cell Line License Agreement with Life Technologies Corporation, dated June 28, 2018 (Filed With SEC on November 13, 2020)
- Global Co-Development and Collaboration Agreement with BeiGene, Ltd. and BeiGene Switzerland GmbH, dated April 8, 2019, as amended by First Amendment, dated December 24, 2019 and... (Filed With SEC on November 13, 2020)
- Amended and Restated Exclusive License Agreement with F1 Oncology, Inc., dated November 22, 2019 (Filed With SEC on November 13, 2020)
- Exclusive License Agreement with BioAtla Holdings, LLC, dated January 1, 2020, as amended by First Amendment to Exclusive License agreement, dated July 7, 2020 (Filed With SEC on November 13, 2020)
- Exclusive License Agreement with Inversagen, LLC, dated March 15, 2019, as amended by First Amendment to Exclusive License Agreement, dated July 7, 2020 (Filed With SEC on November 13, 2020)
